Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection

AIM: To evaluate new therapies for hepatitis C virus (HCV), data about real-world outcomes are needed. METHODS: Outcomes of 223 patients with genotype 1 HCV who started telaprevir- or boceprevir-based triple therapy (May 2011-March 2012) at the Mount Sinai Medical Center were analyzed. Human immunod...

Descripción completa

Detalles Bibliográficos
Autores principales: Bichoupan, Kian, Tandon, Neeta, Martel-Laferriere, Valerie, Patel, Neal M, Sachs, David, Ng, Michel, Schonfeld, Emily A, Pappas, Alexis, Crismale, James, Stivala, Alicia, Khaitova, Viktoriya, Gardenier, Donald, Linderman, Michael, Olson, William, Perumalswami, Ponni V, Schiano, Thomas D, Odin, Joseph A, Liu, Lawrence U, Dieterich, Douglas T, Branch, Andrea D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2017
Materias:
Observational Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395804/
https://www.ncbi.nlm.nih.gov/pubmed/28469811
http://dx.doi.org/10.4254/wjh.v9.i11.551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395804/
https://www.ncbi.nlm.nih.gov/pubmed/28469811
http://dx.doi.org/10.4254/wjh.v9.i11.551

Ejemplares similares